Adelaide A. Hebert, MD

Articles by Adelaide A. Hebert, MD

Adherence, Specialty Pharmacies, and the Future of Precision Pediatric Care

ByAdelaide A. Hebert, MD,Autumn Atkinson, MD

February 9th 2026

Examine adherence challenges, specialty pharmacy support, and emerging precision medicine approaches in pediatric atopic dermatitis and psoriasis.

Steroid Safety, Growth Concerns, and When to Escalate Pediatric Therapy

ByAdelaide A. Hebert, MD,Autumn Atkinson, MD

February 2nd 2026

Understand steroid safety concerns, growth effects, and indications for biologics and oral JAK inhibitors in pediatric skin disease.

Proactive Flare Prevention and Practical Use of Advanced Pediatric Topicals

ByAdelaide A. Hebert, MD,Autumn Atkinson, MD

January 26th 2026

Learn how to set expectations, prevent flares, and choose among advanced topical therapies for pediatric atopic dermatitis and psoriasis.

EHR Collaboration and New Steroid-Sparing Topicals in Pediatric Dermatoses

ByAdelaide A. Hebert, MD,Autumn Atkinson, MD

January 19th 2026

See how shared EHRs support collaborative care and review newer steroid-sparing topical therapies for pediatric atopic dermatitis and psoriasis.

Severe Pediatric Dermatoses: Diagnostic Pitfalls and Early Systemic Therapy

ByAdelaide A. Hebert, MD,Autumn Atkinson, MD

January 12th 2026

Explore diagnostic challenges in severe pediatric skin disease, common management pitfalls, and when to escalate to systemic or biologic therapy.

Differentiating Pediatric Atopic Dermatitis, Psoriasis, and Seborrheic Dermatitis

ByAdelaide A. Hebert, MD,Autumn Atkinson, MD

January 5th 2026

Learn how to distinguish pediatric atopic dermatitis, psoriasis, and seborrheic dermatitis and recognize red flags that warrant dermatology referral.

Implications of Findings on Roflumilast Cream 0.05% for Atopic Dermatitis, with Adelaide Hebert, MD

ByAdelaide A. Hebert, MD

August 4th 2025

This segment of Hebert’s DERM 2025 interview highlights additional conclusions from her team’s data on roflumilast in atopic dermatitis among infants and toddlers.

Safety of Roflumilast Cream 0.05% in Infants and Toddlers with Atopic Dermatitis, with Adelaide Hebert, MD

ByAdelaide A. Hebert, MD

August 1st 2025

In a DERM 2025 conference interview, Hebert highlights takeaways from her team’s findings on roflumilast cream in patients aged 3 months to 2 years with atopic dermatitis.

Safety Profile, Accessibility of Tapinarof Cream 1% for Atopic Dermatitis, with Adelaide Hebert, MD

ByTim Smith,Adelaide A. Hebert, MD

February 6th 2025

This segment of Hebert’s interview features a discussion regarding the safety profile of tapinarof 1% for patients aged 2 years and older with atopic dermatitis.

Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD

ByAdelaide A. Hebert, MD,Tim Smith

February 5th 2025

Adelaide Hebert, MD, discusses the impact of the recent approval for tapinarof cream in the management of atopic dermatitis.

Pediatric Plaque Psoriasis

ByAdelaide A. Hebert, MD

February 29th 2024

This publication was developed independently by MJH Life Sciences Global Medical Affairs. Support for the thought leaders meeting and the publication was provided by Arcutis Biotherapeutics, Inc; The Bristol Myers Squibb Company; Janssen Global Services, LLC; and UCB, Inc.

Beyond Skin Deep: Validating and Transforming SD Patient Care

ByLinda Stein Gold, MD,Neal Bhatia, MD,James Song, MD,Adelaide A. Hebert, MD,Shawn Kwatra, MD

December 14th 2023

Dermatologists end their discussion on seborrheic dermatitis (SD), highlighting key takeaways for patients and clinicians on managing this condition.

Silently Struggling: Discussing the Unseen Burdens of SD

ByLinda Stein Gold, MD,James Song, MD,Shawn Kwatra, MD,Neal Bhatia, MD,Adelaide A. Hebert, MD

December 14th 2023

Experts discuss the profound impact of seborrheic dermatitis on a patients' well-being, examining the common misconceptions, diagnostic delays, and societal judgments that hinder effective management and necessitate enhanced clinical outreach and patient education.

Emerging Therapies in Seborrheic Dermatitis

ByLinda Stein Gold, MD,Neal Bhatia, MD,Shawn Kwatra, MD,James Song, MD,Adelaide A. Hebert, MD

December 14th 2023

Dermatologists discuss the realm of emerging therapies for seborrheic dermatitis (SD), emphasizing the importance of both breakthrough and failed trials, while highlighting the need for scientific rigor and patient-reported outcomes.

Optimizing and Expediting Care: A Novel Treatment for SD

ByLinda Stein Gold, MD,Neal Bhatia, MD,Shawn Kwatra, MD,James Song, MD,Adelaide A. Hebert, MD

December 7th 2023

Experts reflect on the transformative shift in seborrheic dermatitis treatment, offering effective and time-efficient solutions to identify the disease and educate patients about it.

Managing Seborrheic Dermatitis Across All Skin Types

ByLinda Stein Gold, MD,Neal Bhatia, MD,Shawn Kwatra, MD,James Song, MD,Adelaide A. Hebert, MD

December 7th 2023

Dermatologists discuss clinical considerations when treating seborrheic dermatitis across diverse skin types, addressing common symptoms, concerns, and overall efficacy.

Simplifying Treatment Regimens for Patients With SD

ByLinda Stein Gold, MD,Neal Bhatia, MD,Shawn Kwatra, MD,James Song, MD,Adelaide A. Hebert, MD

November 30th 2023

Experts explore the challenges of multi-product topical treatment algorithms for seborrheic dermatitis (SD) and the value of once-a-day solutions in fostering adherence, improved quality of life, and overall better outcomes.

The Safety and Efficacy of Novel SD Treatment

ByLinda Stein Gold, MD,Neal Bhatia, MD,Shawn Kwatra, MD,James Song, MD,Adelaide A. Hebert, MD

November 30th 2023

Dermatologists discuss the safety and efficacy of roflumilast for seborrheic dermatitis (SD), highlighting its tolerability across backgrounds and age groups, safety in pediatric care, and the unmet need it fulfills.

Topical Foam: A Breakthrough in SD Treatment

ByLinda Stein Gold, MD,Neal Bhatia, MD,Shawn Kwatra, MD,James Song, MD,Adelaide A. Hebert, MD

November 27th 2023

Dermatologists discuss a groundbreaking agent, roflumilast, filling a void in seborrheic dermatitis (SD) treatment. These experts highlight patient-reported response to this novel treatment and their own experiences in clinical trials with this drug.

Navigating SD Challenges: Expert Treatment Strategies

ByLinda Stein Gold, MD,Neal Bhatia, MD,Shawn Kwatra, MD,James Song, MD,Adelaide A. Hebert, MD

November 27th 2023

Dermatologists discuss diverse patient presentations and effective treatments for seborrheic dermatitis (SD), addressing over-the-counter product challenges, immune signatures, and treatment nuances in pediatric care.

Prior Treatment Options and Outcomes for SD

ByLinda Stein Gold, MD,Neal Bhatia, MD,Shawn Kwatra, MD,James Song, MD,Adelaide A. Hebert, MD

November 16th 2023

Experts shed light on the challenges of seborrheic dermatitis treatment, emphasizing the historical lack of treatment options and importance of patient education.

The Impact of Seborrheic Dermatitis

ByLinda Stein Gold, MD,Neal Bhatia, MD,Shawn Kwatra, MD,James Song, MD,Adelaide A. Hebert, MD

November 16th 2023

Dermatologists discuss the profound impact of seborrheic dermatitis on an individual’s quality of life, discussing self-reported effects on self-esteem, social interactions, and career trajectories.

Neal Bhatia, MD, and Shawn Kwatra, MD, sit at a table discussing seborrheic dermatitis.

Seborrheic Dermatitis vs. Other Skin Conditions

ByLinda Stein Gold, MD,Neal Bhatia, MD,Shawn Kwatra, MD,James Song, MD,Adelaide A. Hebert, MD

November 9th 2023

Dermatologists discuss differentiating seborrheic dermatitis from conditions like psoriasis, eczema, and lupus, highlighting similarities and differences with other skin conditions.

James Song, MD, and Adelaide Hebert, MD, sit at a table discussing seborrheic dermatitis.

Navigating Seborrheic Dermatitis (SD): An Overview With Expert Perspectives

ByLinda Stein Gold, MD,Neal Bhatia, MD,Shawn Kwatra, MD,James Song, MD,Adelaide A. Hebert, MD

November 9th 2023

Dermatologists introduce this series providing and overview of seborrheic dermatitis (SD), highlighting common causes, contributing factors, and the various ways it may present in different patient populations.

Keeping Physicians Up to Date With AD Advances

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 15th 2023

Experts in dermatology share advice on helping fellow physicians stay apprised of the advances in AD and treat their patients more effectively.

Emerging Treatment Options in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 15th 2023

Expert dermatologists consider ongoing trials and emerging treatment options for the management of AD.

Guidance for Topical Treatment Use Based on BSA in AD

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 15th 2023

Experts in dermatology share general guidance for use of topicals, switching from topical to systemic treatment, and when combination therapy is an option for patients with atopic dermatitis.

Monitoring AD Treatments in Various Age Groups

ByRaj Chovatiya, MD, PhD,Matthew Zirwas, MD,Adelaide A. Hebert, MD,Omar Noor, MD,Peter Lio, MD

March 8th 2023

Omar Noor, MD, and Adelaide A. Hebert, MD, discuss monitoring requirements for various classes of treatments in atopic dermatitis, including topical vs systemic.